advertisement
Abstract #8946 Published in IGR 5-2
Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double masked, parallel clinical trials
Zabriskie N; Netland PAAdvances in Therapy 2003; 20: 92-100
Two double masked, randomized, parallel, multicenter trials of similar design were conducted to compare the IOP lowering efficacy of dual therapy with brimonidine 0.2% and latanoprost 0.005% with the fixed combination of timolol 0.5%/dorzolamide 2% in patients with glaucoma or ocular hypertension. The combination of brimonidine and latanoprost produced significantly greater mean IOP reductions at each visit in both trials. In study 1, the mean reduction at peak drug effect after six weeks was 9.2 mmHg (34.7%) with brimonidine and latanoprost and 6.7 mmHg (26.1%) with timolol/dorzolamide (p = 0.024); respective reductions at week 12 were 9.0 (33.9%) and 6.5 mmHg (25.3%) (p = 0.044). At the month 1 visit in study 2, the mean peak IOP reduction was 10.6 mmHg (39.0%) with dual therapy and 6.3 mmHg (25.1%) with the fixed combination (p = 0.001). After three months, reductions were 9.1 (33.4%) and 6.6 mmHg (26.3%) (p = 0.047). In these studies, the combination of brimonidine and latanoprost provided IOP control superior to that of the fixed combination of timolol/dorzolamide.
Dr. P.A. Netland, Department of Ophthalmology, University of Tennessee, 956 Court Avenue, Memphis, TN 38163, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
